cervical cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with histologically confirmed primary squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix; 2. Patients with histologically confirmed stage IAI (+) LVSI, IA2, IB1, IB2 and IIA1 disease (TNM and 2018 FIGO staging for carcinoma of the uterine cervix); 3. Patients undergoing a Type II/Type III radical hysterectomy (Piver-Rutledge Classification) or Type B/Type C radical hysterectomy (Querleu-Morrow Classification); 4. Patients with adequate bone marrow, renal and hepatic function using Standard International Units: 4.1 WBC > 3.0 x 10^9 cells/L 4.2 Platelets > 100 x 10^9 cells/L 4.3 Creatinine 5 years ago with no current evidence of disease; 8. Females aged 18 years or older; 9. Negative serum pregnancy test 30 days of surgery in premenopausal women and women < 2 years after the onset of menopause.
Exclusion criteria
Exclusion criteria: 1. Patients with evidence of metastatic disease by conventional imaging studies (CT Scan, MRI or PET CT Scan), enlarged pelvic or aortic lymph nodes > 2cm, or histologically positive lymph nodes; 2. Patients with a history of pelvic or abdominal radiotherapy; 3. Uterine size larger than 12 cm in length; 4. Patients with contraindications to surgery or who are unfit for surgery with serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); 5. Patients unable to withstand prolonged lithotomy and steep Trendelenburg position; 6. Patients whose compliance and geographic proximity do not allow adequate follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year survival rate; | — |
Countries
China
Contacts
Shanghai Tenth People's Hospital